Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Senzime

2.68 SEK-0.74 %23/10 12:55
Less than 1K followers

SEZI

NASDAQ Stockholm

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Short Selling
Investor views
Compare
-0.74 %
+0.19 %
-32.07 %
-43.70 %
-50.37 %
-53.95 %
-58.13 %
-86.61 %
-54.84 %

Senzime operates in the medical technology industry and focuses on the development and manufacture of systems for monitoring and diagnostics in healthcare. The portfolio includes systems used to automate and measure the substances glucose and lactate in blood and tissues. The company's products are aimed at healthcare institutions and physicians. The operations are global. Senzime was founded in 1999 and is headquartered in Uppsala, Sweden.

Read more
Market cap
421.34M SEK
Turnover
365.43K SEK
Revenue
104.02M
EBIT %
-117.84 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
29/10
2026

Interim report Q3'26

18/2
2027

Annual report '26

22/4
2027

Interim report Q1'27

All
Webcasts
Press releases
3rd party
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Press release2026-10-21 13:01

Redeye: Senzime (Q3 Preview): A rebound needed to turn the tide

Senzime
Press release2026-10-13 14:45

Senzime lanserar ny prediktiv teknologi för neuromuskulär övervakning

Senzime
Press release2026-10-13 14:45

Senzime Launches Industry-First Predictive Neuromuscular Monitoring Technology

Senzime

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release2026-10-05 16:00

Senzime bekräftar målet om att nå positivt kassaflöde inom det fjärde kvartalet 2026

Senzime
Regulatory press release2026-10-05 16:00

Senzime reaffirms its target of reaching positive cash flow within Q4 2026

Senzime
Press release2026-09-29 17:25

Redeye: Senzime: Business update with a clear message on financing

Senzime
Regulatory press release2026-09-28 15:00

Senzime stärker finansieringen för att stödja strategisk OEM-expansion och vägen mot lönsamhet

Senzime
Regulatory press release2026-09-28 15:00

Senzime strengthens financing to support strategic OEM expansion and path to profitability

Senzime
Press release2026-09-24 16:30

Senzime säkrar kontrakt med stort amerikanskt sjukhusnätverk och stärker basen av återkommande intäkter

Senzime
Press release2026-09-24 16:30

Senzime secures additional major US hospital network contract, expanding adoption of its next-generation neuromuscular monitoring technology

Senzime
Press release2026-08-05 09:00

Senzimes TetraGraph-system tilldelas femårigt nationellt leveransavtal med amerikanska Veterans Affairs

Senzime
Press release2026-08-05 09:00

Senzime awarded exclusive 5-year national supply contract with U.S. Veterans Affairs through its partner TrillaMed

Senzime
Regulatory press release2026-07-16 08:00

Interim report Q2 2026: Strong sensor sales and improved margins, despite continued U.S. monitor market headwinds

Senzime
Regulatory press release2026-07-16 08:00

Delårsrapport Q2 2026: Stark sensorförsäljning och förbättrade marginaler trots fortsatt utmanande marknadsförhållanden i USA för nyförsäljning av monitorer

Senzime
Regulatory press release2026-07-15 21:00

Senzime och Philips Medical Systems ingår långsiktigt partnerskap för utveckling och kommersialisering

Senzime
Regulatory press release2026-07-15 21:00

Senzime and Philips Medical Systems enter development and commercialization partnership

Senzime
Press release2026-07-13 12:00

Inbjudan till presentationer av Senzimes rapport för andra kvartalet 2026

Senzime
Press release2026-07-13 12:00

Invitation to presentations of Senzime’s second quarter 2026 report

Senzime
Press release2026-06-29 09:00

Senzimes TetraGraph-system erhåller ANVISA godkännande i Brasilien

Senzime
Press release2026-06-29 09:00

Senzime’s TetraGraph system receives ANVISA regulatory approval in Brazil

Senzime